Chris Calcaterra, an accomplished inventor based in Coto de Caza, California, has made significant contributions to the field of ophthalmic devices. With a remarkable portfolio of five patents, Calcaterra is dedicated to developing innovative solutions that enhance eye care and improve patient outcomes.

Latest Patents

Among his latest creations, Calcaterra's gonioscopic devices stand out. These devices include a gonioscopic attachment designed to seamlessly connect to a gonioscope. This attachment features atraumatic retention elements that engage the eye, allowing for optimal positioning of the gonioscope relative to the eye. The design ensures that part of the concave distal surface is spaced from the eye and angularly offset to align with the eye’s curvature. Additionally, the gonioscope incorporates a fixation point visible to the subject, improving usability. Furthermore, the device can include a light pipe for direct illumination of the eye, showcasing Calcaterra's innovative approach to enhancing diagnostic capabilities in ophthalmology.

Career Highlights

Chris Calcaterra has built a distinguished career at Glaukos Corporation, where he continues to innovate within the field of ocular devices. His expertise in creating practical solutions for eye care reflects a deep understanding of both engineering and medical needs. Under his guidance and vision, Glaukos Corporation has become a prominent name in ophthalmic technology.

Collaborations

Collaborating with talented colleagues such as Charles Raymond Kalina, Jr. and Thomas W Burns, Calcaterra has been part of a dynamic team committed to advancing eye health technology. These collaborations foster a creative environment that leads to cutting-edge developments in the field.

Conclusion

Chris Calcaterra exemplifies the spirit of innovation within the field of ophthalmology. His pioneering work on gonioscopic devices demonstrates his commitment to improving patient care and enhancing the capabilities of eye specialists. As he continues to push the boundaries of what is possible, Calcaterra remains a vital figure in the landscape of technological advancements in eye care.

This text is generated by artificial intelligence and may not be accurate.